ACTUAL IMPACT OF 68GA-PSMA-11 PET/CT ON THE MANAGEMENT OF PROSTATE CANCER PATIENTS WITH BIOCHEMICAL RECURRENCE.


Calais, Fendler, Eiber, Gartmann, Chu, Nickols, Reiter, Rettig, Marks, Ahlering, Huynh, Slavik, Gupta, Quon, Allen-Auerbach, Czernin, Herrmann. (14-12-2017).



Journal of Nuclear Medicine2017, doi: 10.2967/jnumed.117.202945

Department: 

Research Area B

Abstract: 

Purpose: In this prospective survey of referring physicians, we investigated whether and how Gallium-68 Prostate Specific Membrane Antigen Positron Emission Tomography/Computed Tomography (PSMA-11 PET/CT) affects the actually implemented management of prostate cancer patients wih biochemical recurrence (BCR).

Methods: We conducted a prospective survey of physicians (NCT02940262) who referred 161 patients with prostate cancer BCR (median Prostate Specific Antigen (PSA) value 1.7 ng/ml (range 0.05-202)). Referring physicians completed one questionnaire prior to the scan to indicate the treatment plan without PSMA-11 PET/CT information (Q1; n = 101); one immediately after the scan to denote intended management changes (Q2; n = 101); and one 3 to 6 months later to document the final implemented management (Q3; n = 56). Implemented management was also obtained via electronic chart review and/or patient contact (n = 45).

Results: Complete documented management strategy (Q1+Q2+implemented management) was available in 101/161 patients (63%). Seventy-six of these (75%) had a positive PSMA-11 PET/CT study. The actually implemented management differed from the pre-scan intended treatment plan (Q1) in 54/101 patients (53%). The post-scan intended management (Q2) differed from the pre-scan intended management (Q1) in 62/101 patients (61%); however, these intended changes were not implemented in 29/62 patients (47%). Pelvic nodal and extra-pelvic metastatic disease on PSMA-11 PET/CT (PSMA T0N1M0 and PSMA T0N1M1 patterns) were significantly associated with implemented management changes (P = 0,001, 0.05).

Conclusion: PSMA-11 PET/CT results in actually implemented management changes in more than 50% of prostate cancer patients with BCR (54/101; 53%). However, intended management changes early after PSMA-11 PET/CT frequently differ from actually implemented management changes.